Pharmacoeconomic Analysis of Gilteritinib in the Therapy of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemias with FLT3 Mutation

Background. The implementation of new FLT3-targeted drugs in clinical practice has changed the approaches to the management of patients with acute myeloid leukemias (AML) with FLT3 mutation. One of these drugs is gilteritinib, approved by FDA in 2018 as a drug of choice in the therapy of adult patie...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	A. S. Kolbin, Yuliya Mikhailovna Gomon, Yu. E. Balykina, M. A. Proskurin
Format:	Artigo
Sprache:	Russo
Veröffentlicht:	Practical Medicine Publishing House 2022-01-01
Schriftenreihe:	Клиническая онкогематология
Schlagworte:	gilteritinib flt3 mutation acute myeloid leukemias pharmacoeconomics incremental cost-effectiveness ratio
Online-Zugang:	https://bloodjournal.ru/index.php/coh/article/view/129
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!